Estradiol Tablet 0.5mg

Route: Oral — swallowed tablet.

• Take once daily at the same time each day, with or without food.
• Swallow whole with adequate fluid.
• Consistent daily administration maintains stable hormone levels.

Final dosing is prescriber-determined. The 0.5 mg dose represents the lower end of the oral estradiol dosing spectrum:

• Commonly used as a starting dose or the lowest maintenance dose for menopausal symptom management.
• May be titrated upward (to 1 mg or 2 mg) by the prescriber if symptom control is insufficient.
• Patients with intact uteri require concurrent progestogen — type and schedule determined by prescriber.

• Estradiol 0.5mg (oral): Absorbed from the GI tract and subject to first-pass hepatic conversion to estrone; both circulate and bind ERα and ERβ in target tissues, activating gene transcription involved in thermoregulation, bone remodeling, genitourinary epithelial maintenance, and hepatic protein synthesis. At 0.5 mg, systemic estrogenic effects are present but at the lower end of the therapeutic spectrum.

Clinical Context: The 0.5 mg dose is used to initiate therapy conservatively, particularly in older postmenopausal women, those with mild symptoms, or situations where the lowest effective dose is prioritized. Monitoring is identical to higher-dose oral estradiol — endometrial protection with progestogen in non-hysterectomized patients, annual mammography, and lipid/blood pressure monitoring. Prescribers titrate based on symptom response and serum estradiol levels.

Contraindications:

• Estrogen-dependent malignancies, undiagnosed genital bleeding, active VTE/PE/arterial thromboembolism, active liver disease, thrombophilic disorders, pregnancy.

Warnings & Precautions:

• Endometrial cancer risk with unopposed estrogen in non-hysterectomized women — progestogen required.
• Breast cancer risk with prolonged use.
• Thromboembolic risk (oral route).
• Oral estrogen may increase triglycerides; monitor in susceptible patients.

Drug Interactions:

• CYP3A4 inducers/inhibitors affect estradiol metabolism; thyroid hormone requirements may change.

Common Side Effects: Nausea, breast tenderness, headache, bloating, spotting/breakthrough bleeding (without adequate progestogen).

Store at controlled room temperature (20–25°C / 68–77°F), in a tightly closed container, away from moisture and light. Keep out of reach of children. Observe the beyond-use date assigned by Genesis Compounding.

Why would my prescriber start me at 0.5mg?

Initiating at the lowest effective dose minimizes exposure to estrogen while achieving symptom control. The 0.5 mg dose is appropriate for mild symptoms, older patients, or those where minimal estrogen exposure is a clinical priority. Dose can be titrated upward if symptom control is insufficient.

Do I need a progestogen with this tablet?

Yes, if your uterus is intact — even low-dose unopposed estrogen can stimulate the endometrium over time. Your prescriber will determine the appropriate progestogen type, dose, and schedule.

Is this FDA-approved?

This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding and is not FDA-approved as a finished compounded drug product.

Will 0.5mg be enough to relieve my hot flashes?

Symptom response at 0.5 mg varies by patient. Some women achieve adequate vasomotor relief at this dose; others require titration to 1 mg or 2 mg. Your prescriber will assess response at follow-up and adjust accordingly.